2024³âµµ ¾ÆÁ¨´Ù

Á¦23ȸ Annual Medtech MVP

Tackling Medtech's Timeliest Issues and Opportunities
¸ÞµåÅ×Å©ÀÇ °¡Àå ½Ã±âÀûÀýÇÑ À̽´ ¹× ±âȸ¿¡ ´ëó

2024³â 6¿ù 17-18ÀÏ

Á¦23ȸ Annual Medtech MVP ÄÁÆÛ·±½º´Â ¹Ì±¹ Àü¿ª ÁÖ¿ä ¸ÞµåÅ×Å© ºÐ¾ßÀÇ À̳뺣ÀÌÅÍ ¹× ÅõÀÚÀÚ, °æ¿µÁøÀÌ ¸Å³â ÇÑÀÚ¸®¿¡ ¸ðÀÌ´Â À̺¥Æ®ÀÔ´Ï´Ù. ÀÌ ÄÁÆÛ·±½ºÀÇ Æ¯Â¡À¸·Î¼­ ¸ÞµåÅ×Å© À̳뺣ÀÌÅÍ ¹× ºñÁî´Ï½º ¸®´õ¿ÍÀÇ °ü·Ã ºÐ¾ß¿¡ °üÇÑ ¼ÖÁ÷ÇÑ ³íÀÇ(ÆгΠµð½ºÄ¿¼Ç ¹× 1´ë1 ´ëÈ­) ¹× ±ä¹ÐÇÑ Ä¿¹Â´ÏƼ¿¡¼­ÀÇ Æø³ÐÀº ³×Æ®¿öÅ· µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. °¢Á¾ ±âÁ¶ °­¿¬ ¹× ÆгΠµð½ºÄ¿¼Ç¿¡¼­´Â ÀλçÀÌÆ®¿Í À¯ÀÍÇÑ °ßÇØ ¹× Á¦¾ÈÀ» ¾òÀ» ¼ö ÀÖÀ¸¸ç, ÀÌ°ÍÀÌ Medtech MVP ÇÁ·Î±×·¥ÀÇ Àå±â°£ ¼º°øÀ¸·Î ¿¬°áµÇ°í ÀÖ½À´Ï´Ù. ¿¬»ç´Â ÀÚ½ÅÀÇ Ã¼ÇèÀ¸·ÎºÎÅÍ °¡Ä¡ ÀÖ´Â ½Ã±âÀûÀýÇÑ ÀλçÀÌÆ®¸¦ °øÀ¯ÇÕ´Ï´Ù. ¿ÃÇØ´Â ¸ÞµåÅ×Å©¿¡¼­ DEI ¹× ÀÚ±ÝÁ¶´Þ, ¸¸¼ºÁúȯ ºÐ¾ß¿¡¼­ÀÇ ±â¼ú Çõ½Å, ¼ÒÇÁÆ®¿þ¾î¿Í Çϵå¿þ¾îÀÇ À¶ÇÕ, ÀÓ»ó½ÃÇè¿¡ °üÇÑ FDA ÆгÎ, ¸®¹ö½º ÇÇÄ¡ ¹æ½ÄÀÇ ÆгΠµð½ºÄ¿¼Ç¡¤±âÁ¶ °­¿¬¡¤Á´ãȸ, °ø°³ Åä·Ð µî ½Ã±âÀûÀýÇÑ ÅäÇÈ¿¡ ÃÊÁ¡À» ¸ÂÃä´Ï´Ù. Çõ½ÅÀÇ ÃßÁø¿¡ µµ¿òÀÌ µÇ´Â ¾ÆÀ̵ð¾î °øÀ¯¿Í ³×Æ®¿öÅ·À» ÅëÇØ ¾÷°èÀÇ ¹ßÀü¿¡ °è¼Ó ±â¿©ÇÕ´Ï´Ù.

6¿ù 17ÀÏ ¿ù¿äÀÏ

2:00 pm

Registration Open

3:00 pm

Organizer's Welcome Remarks

3:05 pm

Chairperson's Opening Remarks

Sarah Worrell, CEO, Melodi Health

3:10 pm
PANEL DISCUSSION:

Breakthrough Devices: A Breakthrough for Innovators and Investors?

PANEL MODERATOR:

Christian Johnson, CEO, ScoutMedix

Is Breakthrough Device Designation actually a breakthrough for device innovators, investors, and patients? Does the program expedite timely access to the US market, reduce investor capital risk and increase investor confidence, and elevate brand value for your medical device or portfolio? Should you pursue Breakthrough designation for your medical device or stay course with a traditional regulatory pathway? In this session, MedTech innovators, investors, and former regulators will provide you guidance on whether the Breakthrough Device Program will bring value to your device or portfolio investment based on their experience in the program, industry research, and novel insights from the 95 devices that have obtained FDA market authorization to date. 

PANELISTS:

Mark Domyahn, Partner, JD Lymon

Michael John, VP Head of Cardiovascular Regulatory Affairs, MCRA LLC

Amrinder Singh, Partner, Vensana Capital

Kwame Ulmer, Managing Partner, MedTech Impact Partners; former FDA Branch Chief and Deputy Director

Lisa Wipperman-Heine, Board Director and Medtech Executive

3:50 pm
AVIO MEDTECH PITCH CONTEST

Join us for the Avio MedTech Pitch Contest 2024, where the top three finalists will present their innovative solutions to a panel of expert judges in a tightly scheduled showdown. Experience back-to-back pitches followed by engaging Q&A sessions, leading up to the highly anticipated announcement of the winner. Don't miss this electrifying finale, filled with groundbreaking ideas and insights into the future of medical technology. 

4:50 pm
Simultaneous Breakout Sessions
4:50 pm
BREAKOUT DISCUSSION:Commercializing Digital Health Tech Solutions
PANEL MODERATOR:

Shaye Mandle, Exec Director, AdvaMed Digital Health Tech, AdvaMed

Digital medtech platforms leveraging AI are delivering advanced care for patients and creating powerful solutions for providers. This session will present the investor and company perspective on market access strategies for data and AI in a provider environment.

PANELISTS:

David Kereiakes, Managing Partner, Windham Venture Partners

David Schummers, CEO, Apella

5:20 pm

Networking Welcome Reception

6:30 pm

Close of Day

6¿ù 18ÀÏ È­¿äÀÏ

7:30 am

Registration and Morning Coffee

8:30 am

Organizer's Welcome Remarks

8:35 am

Co-Chairperson's Opening Remarks

Joe Biller, Managing Partner, American Century Private Investments

8:40 am

Sponsored Presentation (Opportunity Available)

9:00 am

KEYNOTE FIRESIDE CHAT: Healthcare Executive Interview

Ashley McEvoy, Former EVP, Worldwide Chair of MedTech, Johnson & Johnson

Ashley McEvoy had an amazing 27-year career journey at Johnson & Johnson, most recently as EVP and Worldwide Group Chairman of J&J MedTech. Today, we will discuss Ashley's optimism for the future of the MedTech industry, her J&J journey and experience executing a massive digital transformation for J&J MedTech, and finally her lessons for future generations of leaders.


Interviewed By:

Renee C Ryan, Independent Director, Audit Committee, RefleXion Medical

9:40 am
PANEL DISCUSSION:

Early-Stage Panel: Strategic Engagement & Raising Capital

PANEL MODERATOR:

Jeff Peters, Venture Partner, Healthcare, OrbiMed Advisors LLC

The Early-Stage Capital Panel will explore the best practices or tips for improving access to early institutional financing. What are the common mistakes? Is partnering with a Strategic early on viable? The panel will feature perspectives from entrepreneurs, venture capitalists, and strategics.

PANELISTS:

Maria Berkman, MD, Director & Head of MedTech, Broadview Ventures

Christopher Kaster, Managing Partner, Cadence Healthcare Ventures

Patrice Kloss, JD, Partner, Fox Rothschild LLP

Rick Sanghera, President & CEO, AtaCor Medical

Darshana Zaveri, Founder and Managing Partner, Catalyst Health Ventures

10:20 am

Introduction of Medtech MVP 2024 Award Recipient

Patrice Kloss, JD, Partner, Fox Rothschild LLP

10:25 am

Interview with Medtech MVP 2024 Award Recipient

Raymond W. Cohen, CEO, Axonics, Inc.

The MVP Award recognizes an individual for extraordinary contributions to a medtech company that has successfully advanced an important new product and delivered strong financial returns. This year's award honors Raymond Cohen, CEO of Axonics for his visionary leadership and innovative solutions that have propelled Axonics to the forefront of the industry. In an exclusive interview with Geoff Pardo, General Partner, Gilde Healthcare, the pair will explore Axonic¡¯s groundbreaking technology, the importance of neuromodulation, and Ray¡¯s storied career, including focusing on key decisions that led him to become an entrepreneur and ultimately the leader of one of the most successful venture-backed medtech companies of our time.

Interviewed By:

Geoffrey Pardo, General Partner, Gilde Healthcare

11:05 am

Networking Coffee Break

11:35 am
Simultaneous Sponsored Presentations
BREAKOUT DISCUSSION:High-Tech Meets Med-Tech - Privacy and FDA Regulatory Considerations for Connected Medical Devices

Speaker to be Announced, Gardner Law

Nathan Downing, Sr Attorney, Gardner Law

Nathan Downing and Paul Rothermel will discuss regulatory and privacy considerations for connected devices, including those utilizing artificial intelligence. In these fast-growing areas of the medical device industry, companies need to contend with FDA¡¯s increasing focus on cybersecurity and the ever-changing state of privacy laws.

BREAKOUT DISCUSSION:Emerging enterprise risk considerations and effective approaches to risk management

Mario Prohasky, Director, Baker Tilly

Proactive and effective risk management remains a challenge with evolving compliance requirements and a constantly shifting business environment. We will focus on key emerging risk areas such as AI technology, the use of digital and data assets, the need for ESG risk mitigation, and new compliance regulations in global markets. We will also analyze how companies bring disparate risks into a cohesive enterprise risk management program and manage risk proactively while providing business value.

BREAKOUT DISCUSSION:Forecasting the Future: Leveraging Lessons from the Most Experienced Minds in Medical Device to Create a Viable Future.
PANEL MODERATOR:

Frank Jaskulke, VP, Innovation, Head of Medical , Medical Alley

PANELISTS:

Christine Horton, Advisor to CAPITA3, President and CEO, Visura Technologies Inc

Thom Gunderson, Chair of Minneapolis Heart Institute Foundation Board of Directors, Former Managing Director, Piper Sandler

Kathleen Tune, Former Managing Partner at Thomas McNerney, Managing Partner, CAPITA3

Scott Ward, Former Chairman and CEO of Cardiovascular Systems, Inc. (acquired by Abbott in 2023), Founder, Raymond Holdings

12:05 pm

Networking Lunch

1:05 pm

Co-Chairperson's Remarks

Aabed Meer, MD, Partner, Questa Capital

1:10 pm
PANEL DISCUSSION:

Late-Stage Companies: M&A vs. IPO Debate

PANEL MODERATOR:

J.P. Peltier, Managing Director, Global Head, Healthcare Investment Banking, Piper Sandler

While the med tech IPO market has been dormant for the past 30 months, the sentiment of both investors and companies is changing. There are 40 plus private high growth med tech companies with the financial profile to consider an IPO path over the next 12 to 18 months. The same profile that qualifies these companies for IPO also makes them attractive acquisition targets ($50+M of sales, high growth, high margins). This panel will dive into the board room and discuss the decision making process of IPO, M&A or dual-path. We also have the opportunity to hear from one of the leading strategic consolidators in the med tech space on their views of the med tech landscape and implications of an open IPO window

PANELISTS:

Joshua Baltzell, Venture Partner, SightLine Partners LLC

Christopher E. Eso, Vice President, Global Head of Corporate and Business Development, M&A and Ventures, Medtronic

Garheng Kong, Founder & Managing Partner, HealthQuest Capital

1:50 pm

Presentation to be Announced

2:10 pm
PANEL DISCUSSION:

Clinical/Regulatory Strategies for Commercial Success

PANEL MODERATOR:

Cynthia Yee, Partner, Vensana Capital

A strong foundation of clinical evidence is integral to commercial success, enabling a company to secure regulatory clearance, support reimbursement, drive physician adoption, and create a durable competitive advantage. This panel explores what it takes to establish a novel technology as the new standard-of-care, with focus on strategies for clinical trial design, execution, and data analysis/communication, as well as the resilience and adaptability needed when plans go awry.

PANELISTS:

James Eadie, MD, Managing Director, Sante Ventures

Margot Goodkin, Chief Medical Officer, SpyGlass Pharma

Sam Roosz, CEO, Crescendo Health

Stacey Pugh, CEO, Endogenex

2:50 pm
PANEL DISCUSSION:

Town Hall-Which Topics are Front-of-Mind?

PANEL MODERATORS:

Buzz Benson, Managing Director, SightLine Partners LLC

Jan Garfinkle, Managing Partner, Arboretum Ventures

Michael Kujak, President & CEO, Francis Medical

This interactive, engaging, and provocative session will explore topics that matter to you and your business. Our panel of industry veterans will share their ideas and points of view, but we want to hear from you! So please come ready to tee up issues you¡¯d like to discuss and be prepared to engage with your peers as we efficiently unpack a variety of topics.

3:30 pm

Networking Refreshment Break

4:00 pm
PANEL DISCUSSION:

Convergence of Software and Hardware

PANEL MODERATOR:

Aabed Meer, MD, Partner, Questa Capital

The panel offers a deep dive into the symbiotic relationship between software and hardware within the healthcare industry. From wearable devices to diagnostic tools, this intersection is reshaping patient care, treatment paradigms, and healthcare delivery. We will explore the transformative potential of this convergence and its implications for patient outcomes.

PANELISTS:

Andy Danielsen, Chair, Mayo Clinic Ventures

Sameer Jafri, CEO, Avive Solutions Inc.

Ron Li, Medical Director for Digital Health, Stanford Health Care Clinical Associate Professor of medicine, Stanford school of Medicine

4:40 pm

Announcement of Pitch Contest Winner- Fireside Chat

4:55 pm
PANEL DISCUSSION:

Innovation in Chronic Disease Indications  

PANEL MODERATOR:

Zack Scott, General Partner, Norwest Venture Partners

PANELISTS:

Kari Snaza, Co-Founder and President, Oasis Health Partners

Rebecca Seidel, Senior Vice President and President, Cardiac Ablation Solutions, Medtronic

Murthy Simhambhatla, PhD, CEO, SetPoint Medical

5:35 pm

Co-Chair's Closing Remarks

Sarah Worrell, CEO, Melodi Health

5:40 pm

Closing Networking Reception

6:50 pm

Close of Summit

* ÁÖÃÖÃø »çÁ¤¿¡ µû¶ó »çÀü ¿¹°í¾øÀÌ ÇÁ·Î±×·¥ÀÌ º¯°æµÉ ¼ö ÀÖ½À´Ï´Ù.